LEXINGTON, Ky., Dec. 11, 2015 (GLOBE NEWSWIRE) -- Transposagen, Inc. today announced that it has entered into a non-exclusive license agreement with the Broad Institute to access intellectual property related to the CRISPR/Cas9 gene editing system.
"Transposagen is pleased to be able to provide innovative tools and services using the CRISPR/Cas9 gene editing technology," commented John Printen, CEO of Transposagen, Inc. "Combination of the CRISPR/Cas9 technology with our Footprint-Free™ Gene Editing System provides an unprecedented ability for precision gene editing without fear of undesired off-target effects.”
The CRISPR/Cas9 technology is incorporated into a suite of gene editing offerings that enable drug discovery researchers to create more accurate disease models, both in vitro and in vivo. Learn more about these products and services at www.transposagenbio.com.
Company Overview
Transposagen, Inc. is a privately-held biotechnology company founded in 2005 to commercialize early gene editing technology for the construction of rodent models of disease. Since that time, Transposagen has significantly increased its scientific offerings to include a suite of gene editing technologies and services that address the research needs of both academic and drug discovery investigators. The company is headquartered in Lexington, KY and employs over 25 researchers, including three PhD scientists who direct the work of our industry-seasoned lab personnel. Located in a newly renovated historic building near downtown Lexington, Transposagen currently occupies over 6,500 ft2 of lab and office space, including a molecular biology lab dedicated to reagent production and product discovery, as well as a cell culture and molecular biology lab dedicated to stem cell and cell line genetic engineering.
Our Mission
Transposagen’s mission is to provide academic and drug discovery researchers with the broadest portfolio of gene editing products and services, empowering their efforts to discover the next generation of therapeutics. We accomplish this mission through internal innovation, in-licensing of cutting-edge technologies, and forming enduring relationships with strategic partners.